1. Home
  2. PRAX vs HXL Comparison

PRAX vs HXL Comparison

Compare PRAX & HXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$305.51

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$102.28

Market Cap

7.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
HXL
Founded
2015
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.3B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
PRAX
HXL
Price
$305.51
$102.28
Analyst Decision
Strong Buy
Buy
Analyst Count
15
10
Target Price
$572.13
$88.30
AVG Volume (30 Days)
329.6K
1.2M
Earning Date
05-08-2026
04-22-2026
Dividend Yield
N/A
0.80%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,893,900,000.00
Revenue This Year
N/A
$10.09
Revenue Next Year
$7,758.26
$12.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$59.79
52 Week High
$366.52
$111.74

Technical Indicators

Market Signals
Indicator
PRAX
HXL
Relative Strength Index (RSI) 46.51 48.81
Support Level $284.87 $81.10
Resistance Level $331.21 $111.74
Average True Range (ATR) 16.88 3.89
MACD -2.16 -0.79
Stochastic Oscillator 34.34 25.82

Price Performance

Historical Comparison
PRAX
HXL

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

Share on Social Networks: